TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Phase 3 trial of obicetrapib, a cholesterol-lowering drug, found lower blood levels of the Alzheimer’s biomarker pTau-217 in a subgroup of participants carrying the ApoE4 risk gene. That result does not show the drug prevents or treats Alzheimer’s; a separate Phase 2b study is starting to test biomarker effects in people with Alzheimer’s hallmarks but no symptoms.
Obicetrapib, an experimental cholesterol-lowering drug, reduced blood levels of the Alzheimer’s biomarker pTau-217 in a subgroup of people carrying the ApoE4 risk gene, according to a Phase 3 trial reported by Being Patient. The finding is a biological signal, not evidence that lowering cholesterol with the drug can prevent or treat Alzheimer’s; a separate Phase 2b study is now testing its effects on biomarkers in people without symptoms.
The Phase 3 study tested obicetrapib, a CETP inhibitor developed by NewAmsterdam Pharma, in people with heart disease or a genetic form of high cholesterol. In a subgroup of 1,727 ApoE4 carriers, the drug lowered blood pTau-217, a biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. The source report does not provide the size of the biomarker change or details of its statistical significance.
The result does not establish that participants experienced improved memory, slower cognitive decline, or reduced dementia risk. Mayo Clinic neurologist David Knopman told Being Patient that the meaning of the biomarker change is unknown. NewAmsterdam Pharma has enrolled the first participant in a separate Phase 2b Alzheimer’s trial, which will examine whether a year of treatment changes Alzheimer’s biomarkers in people who have disease hallmarks but no symptoms.
Earlier evidence on statins is mixed. Two major randomized trials conducted more than a decade ago did not show that statins treated cognitive decline. A newer Danish observational study, published in Lancet Regional Health Europe, followed more than 130,000 people with Type 2 diabetes. It associated starting statins earlier with a 15% lower dementia risk over a decade and starting later with a 10% lower risk. Because this was not a randomized trial, it cannot show that statins caused the differences.
A Biomarker Signal, Not a Treatment Result
The finding offers a reason to investigate whether some cholesterol-lowering drugs affect processes linked to Alzheimer’s, but it does not support prescribing obicetrapib to prevent or treat dementia. A change in a blood marker is not the same as a change in symptoms or disease progression. The ongoing trial may clarify whether the biomarker effect is reproducible in people with signs of Alzheimer’s pathology and whether it warrants studies measuring cognition.
This distinction matters to patients and families weighing prevention claims. Statins remain established medicines for cardiovascular risk reduction, but the evidence described here does not show that they prevent Alzheimer’s. Any decision about cholesterol medication should be made with a qualified health professional for cardiovascular and other individual health needs, not on the assumption that it will protect memory.
Products Worth Considering
Samsung 42-Inch S90H OLED 4K Smart TV Bundle
Dyson V8 Cyclone Cordless Vacuum
Ring Outdoor Cam 4K Plus Battery Security Camera, 3-Pack, White
As an affiliate, we earn on qualifying purchases.
Why Cholesterol Research Returned
Cholesterol in the blood does not pass directly into the brain, where cholesterol is largely managed separately. Researchers are studying whether abnormal cholesterol metabolism within the brain may contribute to Alzheimer’s. ApoE4 is associated with increased risk of both Alzheimer’s and cardiovascular disease and can affect how the body processes cholesterol.
Statins lower blood cholesterol and are widely used to reduce cardiovascular risk, but, according to the source report, they do not readily reach the brain. University of Virginia endocrinologist Heather Ferris said she is skeptical that conventional statins will alter brain cholesterol metabolism. Obicetrapib works differently: it inhibits CETP, a protein involved in moving cholesterol into LDL. Whether that mechanism explains the pTau-217 change, or has any effect on brain function, remains to be tested.
The Danish study adds observational evidence, not a definitive answer. Its authors compared health records over a long period, while factors such as health awareness and other behaviors may differ between people who take statins and those who do not. Knopman noted that such differences make the groups difficult to compare. A randomized trial in healthy adults over 70 also failed to find a dementia-prevention effect from statins, according to Being Patient.
““It’s unknown.””
— David Knopman, Mayo Clinic neurologist, speaking to Being Patient
The Missing Link to Cognitive Benefit
The reported pTau-217 change does not show whether obicetrapib affects memory, thinking, Alzheimer’s onset, or progression. The source report does not give the size of the biomarker reduction, the full statistical results, or evidence that the effect occurred outside the ApoE4 subgroup. It is also unclear whether changes in the blood marker reflect changes in the brain.
The Danish statin findings cannot establish cause and effect, and the report notes potential differences between people who did and did not take the drugs. No long-term randomized trial evidence cited here demonstrates that statins prevent dementia. The evidence therefore leaves open whether cholesterol management has a role in Alzheimer’s beyond its established cardiovascular uses.
The Phase 2b Trial’s Next Test
NewAmsterdam Pharma’s Phase 2b Alzheimer’s study has enrolled its first participant. The trial is designed to test whether one year of obicetrapib treatment changes Alzheimer’s biomarkers in people with disease hallmarks but no symptoms. The source report does not provide the planned enrollment, expected completion date, or results timeline.
Results will need to show more than a biomarker shift before the drug can be considered an Alzheimer’s prevention or treatment. Further research would need to clarify whether the effect is tied to meaningful changes in cognition or disease outcomes and how the benefits and risks compare with existing care.
Key Questions
Does obicetrapib prevent or treat Alzheimer’s?
That has not been shown. A Phase 3 trial reported lower blood pTau-217 in a subgroup of ApoE4 carriers, but the finding does not establish an effect on symptoms, dementia risk, or disease progression.
What did the obicetrapib study measure?
It measured blood levels of pTau-217, an Alzheimer’s-related biomarker, among a subgroup of 1,727 ApoE4 carriers in a trial involving people with heart disease or genetically driven high cholesterol.
Do statins prevent dementia?
The evidence described in the report is mixed. An observational Danish study linked statin use with lower dementia risk, but it cannot establish that statins caused the difference. A randomized trial in healthy adults over 70 did not find a dementia-prevention effect.
What will the Phase 2b trial test?
The trial will examine whether one year of obicetrapib changes Alzheimer’s biomarkers in people who have hallmarks of the disease but no symptoms. The report does not give a timeline for results.
Source: rss
